CVS Health shares surged 7.65% following a strong Q1 2026 earnings report, beating EPS estimates with $2.57 adjusted EPS and 6.2% revenue growth to $100.4 billion. The key driver was Aetna's 52.6% jump in adjusted operating income and improved medical benefit ratio, prompting management to raise full-year EPS guidance to $7.30-$7.50. Analysts are bullish, with price targets raised to around $100 and a 24/7 Wall St. target of $125.45, implying 44% upside. Risks include pharmacy reimbursement pressures and regulatory drug price cuts, but the overall outlook is positive if Aetna's margin recovery continues.
Aetna's latest survey shows U.S. healthcare providers' trust in payers increased to a score of 6.1 from 5.4, reflecting improved perceptions of payer reliability and communication. Providers highlight technology's role in reducing administrative task...
CVS Caremark announced a global settlement with the Federal Trade Commission (FTC) resolving all litigation related to rebate practices, pharmacy network contracting, and vertical integration. The agreement ends ongoing investigations and allows CVS ...
